These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24507016)

  • 41. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
    Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
    J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
    J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
    Sambunaris A; Gommoll C; Chen C; Greenberg WM
    Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
    Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
    Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
    Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression.
    Kent JM; Daly E; Kezic I; Lane R; Lim P; De Smedt H; De Boer P; Van Nueten L; Drevets WC; Ceusters M
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jun; 67():66-73. PubMed ID: 26804646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spotlight on sertraline in the management of major depressive disorder in elderly patients.
    Muijsers RB; Plosker GL; Noble S
    CNS Drugs; 2002; 16(11):789-94. PubMed ID: 12383038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
    Smith EG; Deligiannidis KM; Ulbricht CM; Landolin CS; Patel JK; Rothschild AJ
    J Clin Psychiatry; 2013 Oct; 74(10):966-73. PubMed ID: 24229746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Mathews M; Gommoll C; Chen D; Nunez R; Khan A
    Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.